Phase 1/2 study of pegenzileukin, a pegylated recombinant non-alpha IL-2, with cemiplimab for the treatment of advanced unresectable or metastatic skin cancers [0.03%]
Pegenzileukin（聚乙二醇重组非α型IL-2）与Cemiplimab联合治疗晚期不可切除或转移性皮肤癌Ⅰ/Ⅱ期临床研究
Carlos Rojas,Laurent Mortier,John J Park et al.
Carlos Rojas et al.
Background: Pegenzileukin (SAR444245), a pegylated non-alpha recombinant human interleukin (IL)-2 variant, avoids engagement of the IL-2 receptor α subunit (IL-2Rα) chain and associated toxicities, while retaining engag...
Targeting VEGF signaling and stromal remodeling enhances chemoimmunotherapy efficacy in esophageal cancer [0.03%]
靶向VEGF信号和基质重塑可增强食管癌的化疗免疫疗效
Zhongjian Yu,Wenjia Li,Shiting Xu et al.
Zhongjian Yu et al.
Background: Neoadjuvant chemoimmunotherapy (NACI) has shown promising results in treating esophageal squamous cell carcinoma (ESCC), yet the mechanisms driving its efficacy remain poorly defined, limiting further optimiza...
Novel treatments for novel side effects: a case report and review of baricitinib use in the treatment of chronic inflammatory demyelinating polyneuropathy caused by immune checkpoint inhibitor use [0.03%]
新型药物治疗免疫检查点抑制剂引起的慢性炎症脱髓鞘性多发神经病：一项案例报告及巴瑞克替尼治疗CIDP的回顾分析
Sana Haider,Wei Chua,Bavanthi Balakrishnar et al.
Sana Haider et al.
Immune checkpoint inhibitors (ICIs) have transformed the landscape of solid cancer management. These drugs carry a risk of novel side effects, which have become known as immune-related adverse events (irAEs).Traditionally, irAEs have been m...
Membrane-bound TRAIL-armoring augments CAR-T cells in mesothelin-positive solid malignancies [0.03%]
膜结合的TRAIL-包被增强CAR-T细胞在阳性固体肿瘤中的作用MESO素癌
Alessia Volpe,Juan Zurita,Larissa Shenker et al.
Alessia Volpe et al.
Background: Mesothelin (MSLN)-targeted chimeric antigen receptor (CAR)-T cell therapy shows an effective and long-lasting response in high MSLN-expressing tumors, but fails to treat tumors with heterogeneous levels of ant...
Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort [0.03%]
人源CART22.19治疗复发性儿童B细胞急性淋巴细胞白血病：命名患者队列研究的见解
Anna-Sophia Mast,Peter Lang,Patrick Schlegel et al.
Anna-Sophia Mast et al.
Background: CD19-directed chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment landscape for pediatric B-cell acute lymphoblastic leukemia (B-ALL), yet relapses driven by antigen escape remain a...
KLF4 overexpression in CAR T cells enhances antitumor potency by preventing exhaustion [0.03%]
过表达KLF4可通过防止耗竭增强CAR-T细胞的抗肿瘤功效
Haoqi Wang,Xianglong Meng,Yuanyuan Feng et al.
Haoqi Wang et al.
Background: Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy for patients with refractory or relapsed lymphoma or leukemia. However, inefficient activity and insufficient persistence of CAR T ce...
Immunological consequences of chemotherapy: implications for cancer immunotherapy [0.03%]
化疗的免疫后果：对癌症免疫治疗的意义
Gina G Bishara,Katharine Umphred-Wilson,Scott I Abrams et al.
Gina G Bishara et al.
Despite the success of immunotherapy, chemotherapy remains the backbone of front-line therapy for most patients with cancer. Immune checkpoint inhibitors, T cell engagers, and adoptive cell therapies have traditionally been relegated to sec...
Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma [0.03%]
异常p53促进尿路上皮癌巨噬细胞免疫调控极化及不良临床结局
Yawei Ding,Kaifeng Jin,Xiaohe Su et al.
Yawei Ding et al.
Background: Urothelial carcinoma (UC) exhibits extensive infiltration of tumor-associated macrophages (TAMs). As the most frequently altered gene in UC, TP53 is recognized not only as a guardian of genomic integrity, but ...
Michael Agrez
Michael Agrez
Maintenance of anticancer immunity without compromising immune tolerance remains a challenge. Immunosuppressive regulatory T cells (Tregs) are the guardians of immune tolerance that underpin prevention of autoimmune responses. Tregs express...
CD155 links tumor immunotype to epithelial-directed precision therapy beyond checkpoint inhibition in cervical cancer [0.03%]
宫颈癌中CD155连接肿瘤免疫类型到上皮导向的精确治疗超越检查点抑制作用
Yannick Verhoeven,Delphine Quatannens,Sanne van der Heijden et al.
Yannick Verhoeven et al.
Background: Despite its viral etiology and immunogenic features, cervical cancer shows limited and often short-lived benefit from programmed cell death protein 1 blockade, currently the only approved immunotherapy for thi...